Next Treatments
Back to Eczema

tilrekimig

TypeInjection StagePhase 3 Latest updateUpdated recently. Aug 17, 2026Phase 3 study started

What stands out

New approach in eczema

  • Acts on both IL-4 and TSLP, which no approved eczema treatment currently does; also targets IL-13 (like Adbry and Ebglyss)
  • Binds to IL-13 (a signal molecule that plays a role in allergic inflammation), IL-4 (a signal that helps control antibody production and immune responses) and TSLP (a signal that helps activate and attract immune cells)
Derived from FDA substance registry · UniProt P35225 · UniProt P05112 · UniProt Q969D9 ·
11 US eczema labels (Adbry, Ebglyss, Cibinqo, Eucrisa, Adquey, Dupixent, Nemluvio, Zoryve, Opzelura, Vtama, Rinvoq)
· This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: Aug 22, 2023. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Aug 24, 2026Phase 3 trial postedA Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema ClinicalTrials.gov NCT07783425
  • Aug 17, 2026Phase 3 trial startedA Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema ClinicalTrials.gov NCT07765888
  • Aug 22, 2023Phase 2 trial startedA Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis ClinicalTrials.gov NCT05995964

Sources

Trials